Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fluconazole on the Pharmacokinetics of BI 425809 in Healthy Male Subjects
NCT05076409Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve from 0 to 215 hours and Maximum Measured Concentration. Started Oct 2021; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05076409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076409.